HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by McClenaghan, N. H Articles by Ball, A. J Search for Related Content PubMed PubMed Citation Articles by McClenaghan, N. H Articles by Ball, A. J

¹ School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
² Chemicon International Inc., 28820 Single Oak Drive, Temecula, California 92590, USA

(Requests for offprints should be addressed to A J Ball; Email: aball{at}chemicon.com)

This study examined the effects of glucagon-like peptide-1 (GLP-1) on insulin secretion alone and in combination with sulphonylureas or nateglinide, with particular attention to K_ATP channel-independent insulin secretion. In depolarised cells, GLP-1 significantly augmented glucose-induced K_ATP channel-independent insulin secretion in a glucose concentration-dependent manner. GLP-1 similarly augmented the K_ATP channel-independent insulin-releasing effects of tolbutamide, glibenclamide or nateglinide. Downregulation of protein kinase A (PKA)- or protein kinase C (PKC)-signalling pathways in culture revealed that the K_ATP channel-independent effects of sulphonylureas or nateglinide were critically dependent upon intact PKA and PKC signalling. In contrast, GLP-1 exhibited a reduced but still significant insulin-releasing effect following PKA and PKC downregulation, indicating that GLP-1 can modulate K_ATP channel-independent insulin secretion by protein kinase-dependent and -independent mechanisms. The synergistic insulin-releasing effects of combinatorial GLP-1 and sulphonylurea/nateglinide were lost following PKA- or PKC-desensitisation, despite GLP-1 retaining an insulin-releasing effect, demonstrating that GLP-1 can induce insulin release under conditions where sulphonylureas and nateglinide are no longer effective. Our results provide new insights into the mechanisms of action of GLP-1, and further highlight the promise of GLP-1 or similarly acting analogues alone or in combination with sulphonylureas or meglitinide drugs in type 2 diabetes therapy.

This article has been cited by other articles:

				N. Irwin, M. Moodley, and P. R Flatt Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2009; 9(2): 44 - 52. [Abstract] [PDF]